Search
Search filters
Type
Audience
Category
Issue
Last updated
Displaying 1 - 10 of 10 items.
OCALIVA (obeticholic acid) – New Contraindication for the Treatment of Primary Biliary Cholangitis (PBC)
AlertHealth professional risk communication | 2022-12-05
Janus Kinase Inhibitors and the Risk of Major Adverse Cardiovascular Events, Thrombosis (Including Fatal Events) and Malignancy
AlertHealth professional risk communication | 2022-10-31
IMBRUVICA (ibrutinib) - Risk of Serious and Fatal Cardiac Arrhythmias or Cardiac Failure
AlertHealth professional risk communication | 2022-08-29
Distribution of EVUSHELD (tixagevimab and cilgavimab for injection) with English-Only Vial and Carton Labels
AlertHealth professional risk communication | 2022-04-14
Sodium Acetate Injection, USP - Potential for the Presence of Particulate Matter
AlertHealth professional risk communication | 2022-03-15
0.9% Sodium Chloride Injection, USP and Lactated Ringer’s Injection, USP - Potential Leak During Pressure Infusion
AlertHealth professional risk communication | 2022-03-09
Distribution of NUVAXOVID with English-only Vial and Carton Labels
AlertHealth professional risk communication | 2022-02-23
BEOVU (brolucizumab) – Risk of Intraocular Inflammation, Retinal Vasculitis and/or Retinal Vascular Occlusion
AlertHealth professional risk communication | 2022-02-03
PAXLOVID (nirmatrelvir and ritonavir) - Dosing and Dispensing in Renal Impairment, Risk of Serious Adverse Reactions Due to Drug Interactions, and English-Only Labels
AlertHealth professional risk communication | 2022-01-17
XELJANZ/XELJANZ XR (tofacitinib) – Risk of Major Adverse Cardiovascular Events, Malignancy, Thrombosis and Infection
AlertHealth professional risk communication | 2022-01-12